7 results about "Open angle glaucoma" patented technology

The invention discloses a slit lamp image-based open-angle glaucoma deep learning identification method and system, and relates to the technical field of artificial intelligence and medical diagnosis crossing. The method comprises the steps of preprocessing a slit lamp image and basic clinical data of a target object, processing a standardized image by adopting a pre-trained deep learning model, and performing feature fusion on image depth features and standardized data by adopting a multi-modal feature fusion network. According to the method, automatic classification of two main glaucoma types is achieved, and the problems that in the prior art, distinguishing angle-separating glaucoma from angle-closing glaucoma mainly depends on doctor experience, subjectivity is high, efficiency is not high, traditional chamber angle microscopy examination is high in contact performance, and an existing AI method usually depends on OCT and other special equipment are solved. And objective and efficient auxiliary decision making is provided for clinical diagnosis.

The present application relates to a kind of molecular markers for early diagnosis of glaucoma, the molecular marker is tsRNA, the tsRNA is selected from one or more of tsRNA-5009b-ValCAC and tsRNA-5003c-GlyGCC.The present application finds that relative to healthy control group, the expression of tsRNA-5009b-ValCAC in POAG group patient is significantly down-regulated, its AUC value in ROC curve is 0.717, and diagnosis performance is good, indicating that the tsRNAs can be used as early diagnosis of POAG molecular marker and applied to clinical.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.

This application describes a system to estimate the likelihood of glaucoma from fundus images. The system may include receiving an optic nerve head region of an original image. A variation to the optic nerve head region are applied. A first primary open angle glaucoma likelihood estimate based on the first varied optic nerve head region is generated using a trained convolutional neural network. A second primary open angle glaucoma likelihood estimate based on the second varied optic nerve head region is generated using a trained convolutional neural network. The first primary open angle glaucoma likelihood estimate and the second primary open angle glaucoma likelihood estimate are combined into a final primary open angle glaucoma likelihood estimate. The final primary open angle glaucoma likelihood estimate is presented to a user.

To provide methods for obtaining information on the risk of the exacerbation of broad-defined primary open-angle glaucoma.SOLUTION: The present invention provides a method for obtaining information on the risk of exacerbation of broad-defined primary open-angle glaucoma, comprising: an allele measurement step of measuring alleles for at least 20 SNPs selected from SNPs identified by SNP IDs listed in Table 1 using a biological sample collected from a subject; and an information obtaining step of obtaining information on the risk of exacerbation of the broad-defined primary open-angle glaucoma in the subject based on the allele measurement results.SELECTED DRAWING: Figure 2A

The present application relates to a kind of synthetic method of travoprost for treating primary open-angle glaucoma and high eye pressure.The synthetic method is compared with prior art, with cheap and readily available cori ester as raw material, by 7 steps, with shorter route and higher total yield, the chemical synthesis of travoprost is completed.The synthetic method of travoprost described in the present application, its preparation method is simple, intermediate is stable, environmental protection and economy, reaction is easy to control, and the yield of final product travoprost is high, for the artificial synthesis of travoprost provides a new more effective method, while it can also be used to more simply and more high yield preparation of related analogues of travoprost.